Digital memory assessments and plasma pTau217 enable efficient preclinical Alzheimer's trials.

ABSTRACT:

Background

Preclinical Alzheimer's disease (AD) trials enroll cognitively unimpaired, amyloid-positive older adults; however, most remain clinically stable over typical trial durations. Limited near-term decline reduces statistical power and drives large sample sizes and high costs. Scalable enrichment strategies capable of identifying individuals most likely to decline are critically needed.

Objectives

To determine whether a brief digital memory assessment (DMA) and plasma phosphorylated tau 217 (pTau217), individually or combined, identify preclinical AD participants at elevated risk for cognitive and biological progression, and whether such enrichment reduces clinical trial sample-size requirements.

Design

Analysis of data from the Anti-Amyloid Treatment in Asympto

SUBMITTER: Vanderlip CR 

PROVIDER: S-EPMC12907085 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature